. . . . . . . . . . . . . "2016-07-18T00:00:00Z"^^ . . . . . . . . . "Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer"@en . . . . . . "ensayu cl\u00EDnicu"@ast . . . . . "NCT02642042" . . . "clinical trial"@en . . . "Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer"@en . . . . . . . . . . . . . "Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer"@en . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . "2020-10-15T00:00:00Z"^^ . . "klinisch onderzoek"@nl . . . . . . . "53"^^ . . . . . . . . . . . . . . . "A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies"@en . . . . . . .